<span item_type="fundamental" item_id="9960abcf08623a1052650136cce70ab0" counter_id="ST/US/TSVT" env="prod"></span><span item_type="announcement" item_id="513567319861821697" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 22.94 M, beating the estimate of USD 13.96 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD 0.01, beating the estimate of USD -0.17.</p><p></p><h3>Segment Revenue</h3><ul><li>Abecma generated $59 million in U.S. commercial revenue in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li><li>Total revenues for the three months ended March 31, 2025, were $22.9 million, compared to $12.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Research and development expenses were $5.4 million for the three months ended March 31, 2025, compared to $43.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li><li>Selling, general, and administrative expenses were $14.9 million for the three months ended March 31, 2025, compared to $12.7 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li><li>Net income was $0.5 million for the three months ended March 31, 2025, compared to a net loss of $52.7 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash, cash equivalents, and marketable securities totaled $173.4 million as of March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>2seventy bio reported collaboration revenue of approximately $19.1 million related to the collaboration with BMS for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The acquisition by Bristol Myers Squibb is on track to close in the second quarter of 2025, with the tender offer expected to expire on May 13, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li><li>Following the completion of the transaction, 2seventy bio’s common stock will no longer be listed for trading on Nasdaq.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li><li>In light of the announced transaction, 2seventy bio will not be hosting an earnings conference call or providing financial guidance for 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000036/q12025earningspr_05x07x25.htm"></span></li></ul>

2seventy bio | 8-K: FY2025 Q1 Revenue Beats Estimate at USD 22.94 M